原位核酸分子杂交技术检测宫颈鳞状上皮病变HPV感染

Determination of HPV Genotypes with in Situ Hybridization Technic in Patients with Different Types of Cervical Squamous Epithelial Lesions

目的:观察宫颈鳞状上皮病变过程中HPV6/11、HPV16/18的表达,探讨其测定的临床意义。方法:选择病理诊断为宫颈慢性炎症50例、鳞状上皮乳头状瘤样增生30例、尖锐湿疣30例、上皮内瘤变89例、鳞癌50例共249例石蜡包埋标本,应用原位核酸分子杂交技术对其进行HPV6/11,HPV16/18检测。结果:慢性炎症组HPV6/11阳性表达4%,HPV16/18阳性表达0%;乳头状瘤样增生组HPV6/11阳性表达10%,HPV16/18阳性表达3.3%;尖锐湿疣组HPV6/11阳性表达93.3%,HPV16/18阳性表达23.3%;CIN组中Ⅰ级HPV6/11阳性表达48.9%,HPV16/18阳性表达42.2%;Ⅱ级HPV6/11阳性表达39.1%,HPV16/18阳性表达69.6%;Ⅲ级HPV6/11阳性表达9.5%,HPV16/18阳性表达66.7%;鳞癌组HPV6/11阳性表达6%,HPV16/18阳性表达82%。结论:应用原位核酸分子杂交技术检测宫颈鳞状上皮病变细胞的HPV6/11、HPV16/18,为临床早期诊断、鉴别诊断及评估预后提供可靠的理论依据。

Objective To study the clinical significance of determination of the expression of genotypes of HPV infection （ HPV 6/11, HVP 16/18） in patients with different types of cervical lessions. Methods Expressions of HPV 6/11, HPV 16/18 in biopsy specimens were detected with in situ hybridization technic in （1） 30 patients with chronic cervicitis （2） cervical squamous epithelial papillomatoid hyperplasia （3） 30 patients with cervical condyloma accuminatum （4） 89 patients with cervical intraepithelial neoplasia （LIN） and （5） patients with cervical squamous carcinoma. Results （1） In patients with chronic cervicitis, expression of HPV 6/11 was 4% positive, HPV 16/18 0% positive. （2） In patients with papillomatoid hyperplasia： HPV 6/11 10%, HPV 16/18 3.3% （3） In patients with eondyloma： HPV 6/11 93.3%, HPV 16/18 23.3% （4） In patients with CIN： Grade Ⅰ HPV 6/11 48.9%, HPV 16/18 42.2% Grade Ⅱ HPV 6/11 39.1% and 69.6% respectively, Grade Ⅲ HPV 6/11 HPV 9.5% and HPV 16/18 66.7% respectively. （5） In patients with cervical cancer： HPV 6/11 6% HPV 16/18 82%. Conclusion Determination of genotypes of HPV infection （HPV 6/11, low risk; HPV 16/18, high risk） with in situ hybridization technic in cervical lesion specimens would help to assess the potentiality of development of malignant changes.